David E. Gilham

5.0k total citations
90 papers, 3.7k citations indexed

About

David E. Gilham is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, David E. Gilham has authored 90 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 53 papers in Immunology and 27 papers in Molecular Biology. Recurrent topics in David E. Gilham's work include CAR-T cell therapy research (77 papers), Immune Cell Function and Interaction (35 papers) and Immunotherapy and Immune Responses (26 papers). David E. Gilham is often cited by papers focused on CAR-T cell therapy research (77 papers), Immune Cell Function and Interaction (35 papers) and Immunotherapy and Immune Responses (26 papers). David E. Gilham collaborates with scholars based in United Kingdom, United States and Belgium. David E. Gilham's co-authors include Robert E. Hawkins, Eleanor J. Cheadle, John S. Bridgeman, Hinrich Abken, Dominic G. Rothwell, Peter L. Stern, Н. А. Кириллова, Gray Kueberuwa, Ryan D. Guest and Richard W. Griffiths and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

David E. Gilham

90 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David E. Gilham United Kingdom 35 3.0k 1.6k 1.1k 861 808 90 3.7k
Andrew Kaiser Germany 31 3.1k 1.0× 2.6k 1.6× 1.2k 1.1× 546 0.6× 867 1.1× 56 4.3k
Markus Chmielewski Germany 30 3.5k 1.2× 1.7k 1.0× 1.1k 1.0× 1.2k 1.3× 1.0k 1.3× 38 4.0k
Andreas Hombach Germany 42 4.5k 1.5× 2.5k 1.5× 1.4k 1.3× 1.3k 1.5× 1.4k 1.7× 104 5.4k
Nicole M. Haynes Australia 31 2.3k 0.8× 2.6k 1.6× 1.1k 1.0× 386 0.4× 518 0.6× 58 4.2k
Angelica Loskog Sweden 37 2.8k 0.9× 2.2k 1.4× 1.3k 1.2× 420 0.5× 1.2k 1.5× 103 4.6k
Shivani Srivastava United States 25 1.9k 0.6× 1.8k 1.1× 740 0.7× 484 0.6× 383 0.5× 58 3.3k
Stéphane Depil France 29 2.4k 0.8× 1.6k 1.0× 1.7k 1.6× 549 0.6× 495 0.6× 70 4.0k
Sid P. Kerkar United States 19 2.1k 0.7× 1.6k 0.9× 628 0.6× 418 0.5× 637 0.8× 36 2.7k
Stefanie R. Bailey United States 19 1.6k 0.5× 1.1k 0.7× 699 0.6× 468 0.5× 383 0.5× 35 2.3k
Yun Ji United States 28 3.4k 1.1× 3.9k 2.4× 2.0k 1.9× 519 0.6× 856 1.1× 54 6.3k

Countries citing papers authored by David E. Gilham

Since Specialization
Citations

This map shows the geographic impact of David E. Gilham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Gilham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Gilham more than expected).

Fields of papers citing papers by David E. Gilham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Gilham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Gilham. The network helps show where David E. Gilham may publish in the future.

Co-authorship network of co-authors of David E. Gilham

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Gilham. A scholar is included among the top collaborators of David E. Gilham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Gilham. David E. Gilham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Al‐Homsi, A. Samer, Sébastien Anguille, Dries Deeren, et al.. (2021). Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform. Blood. 138(Supplement 1). 2817–2817. 22 indexed citations
3.
Zhuang, Xiaodong, Federica Maione, Joseph Robinson, et al.. (2020). CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth. JCI Insight. 5(19). 58 indexed citations
4.
5.
Murad, Joana, Susanne H.C. Baumeister, Lillian Werner, et al.. (2018). Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy. Cytotherapy. 20(7). 952–963. 46 indexed citations
6.
Breman, Eytan, et al.. (2018). Overcoming Target Driven Fratricide for T Cell Therapy. Frontiers in Immunology. 9. 2940–2940. 30 indexed citations
7.
8.
Gilham, David E. & John Maher. (2017). ‘Atypical’ CAR T Cells: NKG2D and Erb-B as Examples of Natural Receptor/Ligands to Target Recalcitrant Solid Tumors. Immunotherapy. 9(9). 723–733. 11 indexed citations
9.
Gilham, David E., John Anderson, John S. Bridgeman, et al.. (2015). Adoptive T-Cell Therapy for Cancer in the United Kingdom: A Review of Activity for the British Society of Gene and Cell Therapy Annual Meeting 2015. Human Gene Therapy. 26(5). 276–285. 15 indexed citations
10.
Gilham, David E., et al.. (2014). In vitroeffect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells. Expert Opinion on Pharmacotherapy. 15(11). 1489–1499. 8 indexed citations
11.
Cheadle, Eleanor J., Andreas Hombach, Markus Chmielewski, et al.. (2012). Chimeric Antigen Receptors for T-Cell Based Therapy. Methods in molecular biology. 907. 645–666. 36 indexed citations
12.
Castro, Fernanda, Hui‐Rong Jiang, Jan W. Drijfhout, et al.. (2011). Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy. Cancer Immunology Immunotherapy. 61(7). 1005–1018. 7 indexed citations
13.
Cheadle, Eleanor J., et al.. (2010). Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells. The Journal of Immunology. 184(4). 1885–1896. 61 indexed citations
14.
15.
Waddington, Simon N., Steven J. Howe, Suzanne M. K. Buckley, et al.. (2010). Gene Delivery of a Mutant TGFβ3 Reduces Markers of Scar Tissue Formation After Cutaneous Wounding. Molecular Therapy. 18(12). 2104–2111. 25 indexed citations
16.
Jiang, Hui‐Rong, et al.. (2006). Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors. The Journal of Immunology. 177(7). 4288–4298. 24 indexed citations
17.
Cheadle, Eleanor J., David E. Gilham, Fiona Thistlethwaite, John Radford, & Robert E. Hawkins. (2005). Killing of non‐Hodgkin lymphoma cells by autologous CD19 engineered T cells. British Journal of Haematology. 129(3). 322–332. 17 indexed citations
18.
Guest, Ryan D., Robert E. Hawkins, Н. А. Кириллова, et al.. (2005). The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors. Journal of Immunotherapy. 28(3). 203–211. 255 indexed citations
19.
Eaton, David L., David E. Gilham, Amanda O’Neill, & Robert E. Hawkins. (2002). Retroviral transduction of human peripheral blood lymphocytes with bcl-xL promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Therapy. 9(8). 527–535. 49 indexed citations
20.
Pritchard, Michael P., et al.. (1998). Functional co-expression of CYP2D6 and human NADPHcytochrome P450 reductase in Escherichia coli. Pharmacogenetics. 8(1). 33–42. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew Kaiser Breakdown of academic impact, for papers by Markus Chmielewski Breakdown of academic impact, for papers by Andreas Hombach Breakdown of academic impact, for papers by Nicole M. Haynes Breakdown of academic impact, for papers by Angelica Loskog Breakdown of academic impact, for papers by Shivani Srivastava Breakdown of academic impact, for papers by Stéphane Depil Breakdown of academic impact, for papers by Sid P. Kerkar Breakdown of academic impact, for papers by Stefanie R. Bailey Breakdown of academic impact, for papers by Yun Ji
Rankless by CCL
2026